The invention relates to compounds of formula (I): in which R1 represents pyrazolyl or indazolyl, R2 and R3 especially represent H, halogen, hydroxyl, nitro, cyano, R4, —OR4, —COR4, —OC(═O)R4, —C(═O)OR4, —C(═O)OH, —N(R5)C(═O)R4, —N(R5)C(═O)OR4, —S(O)nR4, —S(O)nOR4, —N(R5)SO2R4, —NY1Y2, —C(═O)NY1Y2, —N(R5)C(═O)NY1Y2, —S(O)nNY1Y2 and —OC(═O)NY1Y2, R4 especially represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl, R5 especially represents H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, Y1 and Y2 especially represent H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylcarboxyl, heteroaryl and heteroarylcarboxy, which are optionally substituted, or Y1 and Y2 form with N an amino ring, n represents 0 to 2, all these radicals being optionally substituted, these products being in all the isomeric forms and the salts, as medicinal products, especially as KDR inhibitors.